Exelixis Inc at Needham Healthcare Conference Transcript
Hello, everybody. My apologies for the late start. My name is Chad Messer. I'm a senior research analyst in biotechnology here at Needham & Company. It's my pleasure to be speaking today with Chris Senner, the Chief Financial Officer; and Andrew Peters, the Vice President of Strategy for Exelixis.
I'm going to go ahead and hand it over to Chris for some opening remarks.
All right. Chad, thank you very much, and thanks again for the invite to speak today. So just before I start, I'd like to remind everyone that we'll be making forward-looking statements during the course of today's discussion. So please refer to our regulatory filings for complete risk -- complete set of risks and disclosures relating to our business. I guess the other thing, too, is we are -- we're just closing up the quarter now, and we're in a quiet period. So we won't be commenting around the first quarter 2020 results. And I guess
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
